Myelodysplastic Syndromes
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-04-13Clinical Trial Update: Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment [Phase 1]
Phase 1 trial of lintuzumab Ac-225, a radiolabeled immunotherapy, for high-risk myelodysplastic syndrome refractory to other treatments has …
-
CLINICAL_TRIALS withdrawal · 2026-03-12Clinical Trial Update: Calprotectin, a Biomarker of COVID-19 Severity (CALPRO) [NA]
A clinical trial evaluating calprotectin (CALPRO) as a biomarker for COVID-19 severity (NCT04953312) has been withdrawn; the study also invo…
-
CLINICAL_TRIALS withdrawal · 2026-02-24Clinical Trial Update: Cryopreserved MMUD BM With PTCy for Hematologic Malignancies [Phase 1]
Phase 1 trial of cryopreserved MMUD bone marrow with post-transplant cyclophosphamide for hematologic malignancies has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-02-13Clinical Trial Update: Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the combination of decitabine, cedazuridine (ASTX727), and ASTX029 (an ERK inhibitor) for patients wit…
-
CLINICAL_TRIALS withdrawal · 2025-11-10Clinical Trial Update: A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies [Phase 1]
A Phase 1 study of Dual-Signaling Protein 107 (DSP107) in hematologic malignancies has been terminated, including studies in Acute Myeloid L…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-04-29Clinical Trial Update: Physical Activity in Transfusion Dependent Patients With Myelodysplastic Syndrome
A clinical trial investigating physical activity in transfusion-dependent patients with myelodysplastic syndrome has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-04-27Clinical Trial Update: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) [Phase 3]
Phase 3 clinical trial evaluating Lemzoparlimab in combination with azacitidine versus azacitidine alone in higher-risk myelodysplastic synd…
-
CLINICAL_TRIALS withdrawal · 2024-10-09Clinical Trial Update: A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes
This clinical trial update describes a retrospective real-world study of treatment patterns and outcomes in myelodysplastic syndromes, but t…
-
CLINICAL_TRIALS withdrawal · 2024-06-14Clinical Trial Update: Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant [Phase 2]
A Phase 2 trial evaluating adding venetoclax to high-dose chemotherapy before a mismatched allogeneic stem cell transplant for acute myeloid…
-
CLINICAL_TRIALS withdrawal · 2024-04-29Clinical Trial Update: High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD [Phase 1, Phase 2]
The trial update indicates that the Phase 1/2 study of high-dose post-transplant cyclophosphamide, bortezomib, and sitagliptin for preventio…
-
CLINICAL_TRIALS withdrawal · 2023-11-24Clinical Trial Update: Transfusion Effects in Myelodysplastic Patients: Limiting Exposure [Phase 4]
Phase 4 trial on transfusion effects in myelodysplastic syndromes was withdrawn.
-
EMA withdrawal · 2023-07-10EMA Withdrawn: Lenalidomide Krka d.d. (lenalidomide hydrochloride hydrate) — Krka, d.d., Novo mesto
The EMA withdrew lenalidomide hydrochloride hydrate (Krka) from the market for multiple indications including multiple myeloma, follicular l…
-
EMA withdrawal · 2022-07-05EMA Withdrawn: Imatinib Actavis (imatinib) — Actavis Group PTC ehf
EMA withdrawn Imatinib Actavis (imatinib) from the market, with indications including chronic myeloid leukemia, precursor B-ALL/lymphoma, my…
-
EMA withdrawal · 2021-08-04EMA Withdrawn: Azacitidine Celgene (azacitidine) — Celgene Europe BV
The EMA has withdrawn the azacitidine product Celgene Europe BV from the market.
-
CLINICAL_TRIALS withdrawal · 2018-07-24Clinical Trial Update: Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating PD-616 in combination with cytarabine for acute myeloid leukemia and myelodysplastic syndromes has bee…
-
CLINICAL_TRIALS withdrawal · 2018-03-30Clinical Trial Update: Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS [Phase 2]
A Phase II study evaluating maintenance therapy with 5-azacitidine after stem cell transplant in acute myeloid leukemia or myelodysplastic s…
-
CLINICAL_TRIALS withdrawal · 2017-12-05Clinical Trial Update: StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies [Phase 2]
Phase 2 trial evaluating StemRegenin-1-expanded versus unexpanded umbilical cord blood for high-risk hematologic malignancies has been withd…
-
CLINICAL_TRIALS withdrawal · 2017-08-31Clinical Trial Update: iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML
A clinical trial (NCT03138395) investigating monitoring circulating cancer DNA after chemotherapy in Acute myeloid leukemia and Myelodysplas…
-
CLINICAL_TRIALS withdrawal · 2017-07-02Clinical Trial Update: Metoclopramide to Treat Anemia in Patients With Myelodysplastic Syndrome (MDS) [Phase 2]
Phase 2 trial evaluating metoclopramide for anemia in patients with myelodysplastic syndromes has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-06-23Clinical Trial Update: Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS) [Phase 1, Phase 2]
A Phase 1/2 trial evaluating 5-day dosing of ON 01910.Na in patients with myelodysplastic syndromes across risk categories, which has been w…
-
CLINICAL_TRIALS withdrawal · 2017-06-02Clinical Trial Update: Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]
Phase 1/Phase 2 dose-escalation trial of ponatinib, a FLT3 inhibitor, with and without 5-azacytidine in FLT3-mutated acute myeloid leukemia …
-
CLINICAL_TRIALS withdrawal · 2017-05-08Clinical Trial Update: Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) [Phase 1]
A Phase 1 trial evaluating pacritinib in combination with low-dose decitabine for intermediate-high risk myelofibrosis and related myeloprol…
-
CLINICAL_TRIALS withdrawal · 2017-05-03Clinical Trial Update: A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS) [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating omacetaxine, azacitidine, and G-CSF for myelodysplastic syndromes has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-09-20Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) [Phase 2]
A Phase 2 trial of epoetin alfa in anemic patients with low- or intermediate-1 risk myelodysplastic syndromes has been withdrawn from develo…
-
CLINICAL_TRIALS withdrawal · 2016-07-14Clinical Trial Update: Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies [Phase 2]
A Phase 2 clinical trial evaluating single or double donor umbilical cord blood transplant for high-risk hematologic malignancies has been w…